• About
  • Advertise
  • Privacy Policy
  • Contact
Over View - Your Daily News Source
  • Home
  • News
    • Business
    • Politics
    • Science
  • Lifestyle
    • Food
    • Travel
    • Health
    • Fashion
  • Entertainment
    • Entertainment
    • Sports
  • Tech
No Result
View All Result
  • Home
  • News
    • Business
    • Politics
    • Science
  • Lifestyle
    • Food
    • Travel
    • Health
    • Fashion
  • Entertainment
    • Entertainment
    • Sports
  • Tech
No Result
View All Result
Over View - Your Daily News Source
No Result
View All Result
Home News Science

Experimental compound burns fat without sacrificing muscle

admin by admin
November 20, 2026
in Science
0
Experimental compound burns fat without sacrificing muscle
0
SHARES
2
VIEWS

A new approach to weight loss could help the body burn more fat while preserving muscle, potentially overcoming one of the major drawbacks of existing obesity treatments. Researchers at the University of California, Berkeley, have identified a compound that increases the amount of energy the body uses rather than simply reducing how much food a person eats.

In experiments with mice, the compound improved blood sugar regulation, reduced harmful blood fats, and helped obese animals lose fat without a significant reduction in lean muscle mass. It also increased energy expenditure by up to 18%, even though the mice did not become more physically active or experience an increase in body temperature.

The findings, published in Science Advances, suggest a promising new direction for treating obesity, diabetes, and fatty liver disease. The experimental compound also appeared to enhance the benefits of popular weight-loss medications such as Ozempic and Wegovy when the treatments were used together. However, its effectiveness and safety have not yet been established in humans.

A Different Approach to Weight Loss Than Ozempic

Over the past five years, medications known as GLP-1 drugs have transformed the treatment of obesity and other metabolic conditions, including diabetes and fatty liver disease. Drugs marketed as Ozempic, Wegovy, Mounjaro, and Zepbound have helped many patients achieve substantial weight loss while improving their ability to regulate blood sugar.

Despite these benefits, the medications have important limitations. Nausea and other digestive problems can make treatment difficult for some patients. Because these drugs reduce appetite and food consumption, they can also increase the risk of inadequate nutrition and loss of muscle mass. Over time, losing too much muscle can contribute to weakness, frailty, and other health complications.

Berkeley researchers wanted to investigate a fundamentally different strategy. Rather than focusing on reducing calorie intake, they explored whether it would be possible to increase the amount of energy the body burns.

This process, known as energy expenditure, includes the calories used to maintain basic bodily functions, regulate metabolism, and support everyday activities. Increasing energy expenditure could potentially help people lose weight without relying exclusively on eating less.

“Body weight responds to two levers: taking in fewer calories, or spending more energy,” said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. “GLP-1s work almost entirely on the first, so we went after the second.”

A Compound That Burns Fat While Preserving Muscle

The researchers focused on a molecule called 5-tetradecyloxy-2-furoic acid (TOFA), which has an unusual combination of effects on the body’s metabolism.

TOFA interferes with the production of lipids, a broad category of fatty substances that includes cholesterol and triglycerides. These molecules serve important functions, but excessive levels of certain lipids can contribute to metabolic disorders and cardiovascular disease.

At the same time, TOFA activates genes involved in taking up and burning fat for energy. This combination allows the compound to influence both how the body produces fat and how it uses fat as fuel.

In mice, treatment with TOFA produced several encouraging results. The animals became more sensitive to insulin, the hormone that helps move glucose from the bloodstream into cells. Improved insulin sensitivity makes it easier for the body to control blood sugar, an important benefit for people with diabetes or insulin resistance.

The compound also lowered triglyceride levels and improved characteristics of fatty liver disease, a condition in which excess fat accumulates inside liver cells and can eventually interfere with liver function.

Perhaps most notably, obese mice treated with TOFA lost weight primarily through reductions in body fat, without experiencing significant losses of lean muscle mass. This distinction could be especially valuable because maintaining muscle is important for strength, mobility, and long-term metabolic health.

How TOFA Increases Energy Burning by 18%

Although TOFA was originally discovered in the 1970s, the new research uncovered additional properties that could make it particularly useful for treating metabolic disease.

The compound belongs to a group of substances known as ACC inhibitors. These compounds interfere with enzymes that help the body manufacture fatty acids, effectively slowing the production of certain fats.

Other ACC inhibitors have previously advanced to mid-stage clinical trials, but none has been approved to treat metabolic diseases. One major obstacle has been an unexpected side effect: many of these compounds increase triglycerides in the blood, potentially raising the risk of heart problems.

The Berkeley team discovered that TOFA does more than inhibit ACC. It also activates two cellular receptors called PPARα and PPARδ, which help regulate the genes responsible for fat metabolism.

These receptors function as molecular switches. When activated, they stimulate processes that allow cells to absorb fatty acids and break them down to produce energy. In effect, TOFA simultaneously reduces the production of certain fats and encourages the body to burn fat that is already available.

In mice, this activity increased energy expenditure by as much as 18%, without requiring additional physical activity or raising body temperature. Unlike other ACC inhibitors, TOFA also did not cause triglyceride levels to rise, potentially because of its additional effects on fat metabolism.

“TOFA appears to engage a coordinated metabolic response,” said study first author Justin Y. Lee, a postdoctoral student at UCSF who conducted the research as a Ph.D. student at Berkeley. “It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively.”

To understand whether these effects could be reproduced with separate treatments, the scientists gave mice a combination of two different compounds. One blocked lipid production, while the other stimulated energy expenditure.

Surprisingly, this two-compound approach was less effective at improving overall metabolic health than TOFA alone. The finding suggests that TOFA’s ability to influence multiple metabolic processes through a single molecule may be an important part of its effectiveness.

Could TOFA Make Ozempic and Wegovy More Effective?

The researchers also investigated whether TOFA could improve the results of existing GLP-1 medications.

They tested the compound alongside semaglutide, the active ingredient in Ozempic and Wegovy, as well as tirzepatide, which is marketed as Mounjaro and Zepbound.

These medications primarily help people lose weight by reducing appetite and food intake. TOFA, by contrast, targets the other side of the energy balance equation by increasing how much energy the body expends.

When the researchers combined TOFA with these medications in mice, the results were more favorable than those produced by either treatment alone. The combinations led to greater improvements in body weight, blood glucose regulation, insulin levels, and triglycerides.

This suggests that treatments targeting calorie intake and energy expenditure could potentially work together to produce stronger metabolic benefits.

“In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement,” Näär said.

In other words, the researchers do not necessarily envision TOFA replacing medications such as Ozempic or Wegovy. Instead, it could eventually become an additional treatment that helps address obesity and related metabolic conditions through a different biological mechanism.

A Promising Discovery, but Human Trials Are Still Needed

Despite the encouraging results, the researchers emphasize that TOFA remains an experimental compound. All the findings so far come from animal studies, and scientists have not yet established whether it is safe or effective in humans.

Further research will be necessary to determine whether the same metabolic improvements can be achieved in people and whether the treatment could offer meaningful advantages over existing medications.

To help move the research toward potential clinical applications, the Berkeley scientists have established a biotechnology company called ReRx Therapeutics. The effort has received support from the university’s life sciences entrepreneurship network, including Nucleate and Berkeley SkyDeck.

If the findings eventually translate to humans, TOFA could represent an important addition to the growing range of treatments for obesity and diabetes. By encouraging the body to use more energy while helping preserve muscle, the compound points toward a potentially different way to achieve healthier weight loss.

The research was funded through discretionary resources provided by UC Berkeley, with additional support from the UCSF Liver Center and the University of Michigan Animal Phenotyping Core.

Additional authors include Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang and Kook Son of Berkeley; Gracia Bonilla, Kashish Chetal and Ruslan I. Sadreyev of Massachusetts General Hospital; Kosuke Watari and Michael Karin of the University of California, San Diego; Christina Papa and Bilal N. Sheikh of the Helmholtz Center Munich; Prabha Ibrahim of ReRx Therapeutics.

Read More

Previous Post

Hulu has an alien invasion thriller that’s almost completely silent, and it’s terrifying

Next Post

Mercedes F1 apporte un nouveau turbo : Sainz, Antonelli et Piastri pénalisés

Next Post
Mercedes F1 apporte un nouveau turbo : Sainz, Antonelli et Piastri pénalisés

Mercedes F1 apporte un nouveau turbo : Sainz, Antonelli et Piastri pénalisés

  • About
  • Advertise
  • Privacy Policy
  • Contact

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Entertainment
    • Entertainment
    • Sports
  • Lifestyle
    • Fashion
    • Health
    • Travel
    • Food
  • News
    • Business
    • Politics
    • Science
  • Tech

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.